Metropolis Healthcare Ltd vs Syngene International Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 25, 2026

Key Highlights

The Latest Trading Price of Metropolis Healthcare Ltd is ₹ 522.95 as of 23 Oct 15:30 . The P/E Ratio of Metropolis Healthcare Ltd changed from 62.6 on March 2021 to 47.3 on March 2026 . This represents a CAGR of -4.56% over 6 yearsThe P/E Ratio of Syngene International Ltd changed from 53.7 on March 2021 to 49.7 on March 2026 . This represents a CAGR of -1.28% over 6 years The Market Cap of Metropolis Healthcare Ltd changed from ₹ 11455 crore on March 2021 to ₹ 8992 crore on March 2026 . This represents a CAGR of -3.95% over 6 yearsThe Market Cap of Syngene International Ltd changed from ₹ 21734 crore on March 2021 to ₹ 15724 crore on March 2026 . This represents a CAGR of -5.25% over 6 years The revenue of Metropolis Healthcare Ltd for the Jun '26 is ₹ 455.32 crore as compare to the Mar '26 revenue of ₹ 432.95 crore. This represent the growth of 5.17% The revenue of Syngene International Ltd for the Jun '26 is ₹ 761.3 crore as compare to the Mar '26 revenue of ₹ 1058 crore. This represent the decline of -28.09% The ebitda of Metropolis Healthcare Ltd for the Jun '26 is ₹ 116.3 crore as compare to the Mar '26 ebitda of ₹ 116.29 crore. This represent the growth of 0.01% The ebitda of Syngene International Ltd for the Jun '26 is ₹ 102.6 crore as compare to the Mar '26 ebitda of ₹ 319.6 crore. This represent the decline of -67.9% The net profit of Metropolis Healthcare Ltd changed from ₹ 38.11 crore to ₹ 56.88 crore over 9 quarters. This represents a CAGR of 19.48% The net profit of Syngene International Ltd changed from ₹ 75.7 crore to ₹ -9 crore over 9 quarters. This represents a CAGR of NaN% The Dividend Payout of Metropolis Healthcare Ltd changed from 20.69 % on March 2021 to 65.83 % on March 2026 . This represents a CAGR of 21.28% over 6 yearsThe Dividend Payout of Syngene International Ltd changed from 10.18 % on March 2022 to 16.52 % on March 2026 . This represents a CAGR of 10.17% over 5 years .

About Metropolis Healthcare Ltd

Dr. Sushil Kanubhai Shah, one of the Promoters, commenced pathology business in January 1980 as a partnership firm in the name of Dr. V. K. Desai's Hospital, having Dr. Kanubhai M. Shah, Dr. Sushil Kanubhai Shah and Dr. Vasant Kalyandas Desai as partners.
The partnership was continued by Dr. Sushil Kanubhai Shah, Dr. Kanubhai M. Shah and Dr. Duru Sushil Shah from September 30, 1981 onwards.
In June 1989, upon death of Dr. Kanubhai M. Shah, the partnership was continued by Dr. Sushil Kanubhai Shah and Dr. Duru Sushil Shah.
Prior to March 18, 1995, Dr. Sushil Kanubhai Shah was also carrying on a business of radioimmunoassay and pathology laboratory on a sole proprietorship basis.
On March 20, 1995, the said sole proprietorship business was converted into a partnership with Dr. Sushil Kanubhai Shah, Dr.

About Syngene International Ltd

Syngene International Limited is an integrated research, development and manufacturing services organization serving global pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical sectors.
Headquartered in India, the operations are driven by its highly qualified teams comprising 5641 scientists and its state-of-the-art facilities, spread over 2.5 million sq. ft., across 3 locations in India: Bangalore, Hyderabad and Mangalore.
The Company operate into 4 business divisions comprising of Discovery Services, Development Services, Manufacturing Services and the Dedicated Centers. Syngene International Limited was incorporated at Bangalore in 1993.
The Company was promoted by Biocon and Kiran Mazumdar Shaw, a promoter of Biocon Limited.
The Company's health-related services extend across all major therapeutic areas and modalities.

FAQs for the comparison of Metropolis Healthcare Ltd and Syngene International Ltd

Which company has a larger market capitalization, Metropolis Healthcare Ltd or Syngene International Ltd?

Market cap of Metropolis Healthcare Ltd is 10,849 Cr while Market cap of Syngene International Ltd is 14,810 Cr

What are the key factors driving the stock performance of Metropolis Healthcare Ltd and Syngene International Ltd?

The stock performance of Metropolis Healthcare Ltd and Syngene International Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Metropolis Healthcare Ltd and Syngene International Ltd?

As of October 25, 2026, the Metropolis Healthcare Ltd stock price is INR ₹522.95. On the other hand, Syngene International Ltd stock price is INR ₹366.9.

How do dividend payouts of Metropolis Healthcare Ltd and Syngene International Ltd compare?

To compare the dividend payouts of Metropolis Healthcare Ltd and Syngene International Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.